Comparison of two hormone replacement regimens — influence on lipoproteins and bone mineral content

Long-term sequential treatment with combined estradiol valerate and cyproterone acetate in early postmenopause

“…Moreover, genitourinary symptoms of estrogen depletion are markedly improved, so that sexual function is also restored in the context of a complex interplay between physical and psychological dynamics. Our results lend further support to previous findings of improved climacteric symptoms together with a mental tonic effect of EV/CPA (19,20). In this regard, we have shown that the efficacy of the EV/CPA combination may well last for an indefinite number of years.…”

The effects of six months of treatment with a low‐dose of conjugated oestrogens in menopausal women

“…The most prominent changes of both hormones were seen in phase B (Table 2). The percentage increases of E levels and decreases of FSH in the higher‐dose groups 2 and 3 were comparable with those reported by others (Castelo‐Branco et al ., 1992; Hirvonen et al ., 1990; Kaufman, 1997). A dose of 0.3 mg CEE per day resulted in a 102% rise of serum E concentrations.…”

GnRH agonists and add‐back therapy: is there a perfect combination?

“…Over several years a daily dose of 1 mg prevented menopausal bone loss in 39% of women, (0.625 mg/day of conjugated oestrogen protected 33%) 91 . When combined with 1 mg cyproterone acetate daily, 2 mg of oestradiol valerate totally prevented bone loss 92 . Transdermal preparations have also been evaluated, 0.05 mg/day transdermal 17 beta oestradiol seems to be the minimum effective dose in preventing bone loss from the spine 93,94 .…”